Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > human immunodeficiency virus therapeutics market
Get a free sample of Human Immunodeficiency Virus (HIV) Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Human Immunodeficiency Virus (HIV) Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The global market is moderately fragmented, with key players holding significant market shares. Leading vendors such as Gilead Sciences, ViiV Healthcare, and Bristol Myers Squibb maintain a strong presence due to their innovative products, including Truvada, Dolutegravir, and Isentress. However, the rise of generic drugs and new market entrants has created a competitive, multi-tiered environment. Smaller companies are increasingly establishing their presence by offering lower-cost alternatives or focusing on specific patient needs, such as drug-resistant HIV strains or personalized treatment options.
Some of the eminent market participants operating in the human immunodeficiency virus therapeutics industry include:
Branded drugs held a 74.5% market share in 2024, supported by increasing prescriptions for fixed-dose combinations like Biktarvy, Genvoya, and Triumeq.
The global HIV therapeutics industry was valued at USD 39 billion in 2024 and is projected to grow at a 3.5% CAGR from 2025 to 2034, driven by the high incidence of HIV infections and advancements in therapeutic treatments.
Key players in the market include AbbVie, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Gilead Sciences, Hetero Drugs, and Johnson & Johnson.
The U.S. led the North American HIV therapeutics market with a revenue of approximately USD 14.5 billion in 2024, driven by increased PrEP prescriptions and expanded HIV testing.